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Abstract
For diffuse large B-cell lymphoma (DLBCL) patients progressing after autologous haematopoietic 
cell transplantation (autoHCT), allogeneic HCT (alloHCT) is often considered, although limited 
information is available to guide patient selection. Using the Center for International Blood and 
Marrow Transplant Research (CIBMTR) database, we identified 503 patients who underwent 
alloHCT after disease progression/relapse following a prior autoHCT. The 3-year probabilities of 
non-relapse mortality, progression/relapse, progression-free survival (PFS) and overall survival 
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(OS) were 30%, 38%, 31% and 37% respectively. Factors associated with inferior PFS on 
multivariate analysis included Karnofsky performance status (KPS) <80, chemoresistance, 
autoHCT to alloHCT interval <1-year and myeloablative conditioning. Factors associated with 
worse OS on multivariate analysis included KPS<80, chemoresistance and myeloablative 
conditioning. Three adverse prognostic factors were used to construct a prognostic model for PFS, 
including KPS<80 (4 points), autoHCT to alloHCT interval <1-year (2 points) and chemoresistant 
disease at alloHCT (5 points). This CIBMTR prognostic model classified patients into four 
groups: low-risk (0 points), intermediate-risk (2–5 points), high-risk (6–9 points) or very high-risk 
(11points), predicting 3-year PFS of 40%, 32%, 11% and 6%, respectively, with 3-year OS 
probabilities of 43%, 39%, 19% and 11% respectively. In conclusion, the CIBMTR prognostic 
model identifies a subgroup of DLBCL patients experiencing long-term survival with alloHCT 
after a failed prior autoHCT.
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 INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) accounts for 30% of non-Hodgkin lymphoma 
(NHL) cases diagnosed in the United States annually. Following the incorporation of 
rituximab into treatment regimens, approximately 60% of DLBCL cases are now cured with 
frontline therapy. Despite overall improvements in the outcomes of DLBCL, about 30–40% 
of patients develop relapsed or refractory disease. Autologous haematopoietic cell 
transplantation (autoHCT) became the standard-of-care for chemosensitive relapsed or 
refractory DLBCL after the PARMA trial showed a benefit for autoHCT over conventional 
second-line therapy.(Philip et al, 1995) More recently, the CORAL (Collaborative Trial in 
Relapsed Aggressive Lymphoma) study provided important information regarding outcomes 
of relapsed or refractory DLBCL in the rituximab-era. In this study, 53% of patients who 
underwent an autoHCT were event-free at 3-years.(Gisselbrecht et al, 2010) Contemporary 
registry data confirm these observations, reporting 3-year progression-free survival (PFS) 
rates of 45–50% following autoHCT.(Fenske et al, 2009, Mounier et al, 2012, Hamadani et 
al, 2014) These data underscore the fact that a significant subset of DLBCL patients who 
undergo autoHCT will eventually relapse.
The prognosis for patients with recurrent disease following autoHCT is poor, with no 
consensus on the optimal therapy. There is evidence to support a graft-versus-lymphoma 
(GVL) effect in DLBCL (Bishop et al, 2008, Rezvani et al, 2008, Hamadani et al, 2013), and 
an allogeneic (allo-) HCT is generally considered to be the only potentially curative option 
for DLBCL patients who relapse after an autoHCT.(Hamadani et al, 2013, Thomson et al, 
2009, Sirvent et al, 2010, Bacher et al, 2012, Klyuchnikov et al, 2014) However, the 
literature is limited regarding the outcomes of alloHCT, specifically in DLBCL patients who 
have relapsed after an autoHCT.
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With many patients undergoing autoHCT for DLBCL each year, and with approximately 
40–50% of those transplants ultimately failing, the decision of whether to pursue an 
alloHCT for a DLBCL patient who has progressed after an autoHCT is, unfortunately, a 
common clinical dilemma. No prognostic models are currently available to counsel such 
patients regarding their expected survival outcomes following alloHCT. We therefore sought 
to develop a prognostic model for DLBCL patients undergoing allografting after a failed 
prior autoHCT, utilizing clinical factors readily available immediately before alloHCT.
 MATERIALS AND METHODS
 Data sources
The Center for International Blood and Marrow Transplant Research (CIBMTR) is a 
working group of more than 500 transplantation centres worldwide that contribute detailed 
data on HCT to a statistical centre at the Medical College of Wisconsin. Participating centres 
are required to report all transplantations consecutively; patients are followed longitudinally 
and compliance is monitored by on-site audits. Computerized checks for discrepancies, 
physicians’ review of submitted data and on-site audits of participating centres ensure data 
quality. Observational studies conducted by the CIBMTR are performed in compliance with 
all applicable federal regulations pertaining to the protection of human research participants.
The CIBMTR collects data at two levels: Transplant Essential Data (TED) and 
Comprehensive Report Form (CRF) data. TED data include disease type, age, gender, pre-
HCT disease stage and chemotherapy-responsiveness, date of diagnosis, graft type (bone 
marrow- and/or blood-derived stem cells), conditioning regimen, post-transplant disease 
progression and survival, development of a new malignancy and cause of death. All 
CIBMTR centres contribute TED data. More detailed disease and pre- and post-transplant 
clinical information are collected on a subset of registered patients selected for CRF data by 
a weighted randomization scheme. TED and CRF level data are collected pre-transplant, 100 
days and six months post-HCT and annually thereafter or until death. Data for the current 
analysis were retrieved from CIBMTR (TED and CRF) report forms.
 Patients
Adult (≥18 years) patients with relapsed/refractory DLBCL, undergoing alloHCT between 
2000 and 2012 after experiencing a relapse or progression following a prior autoHCT were 
included in this study. Eligible donors included human leucocyte antigen (HLA)-identical 
siblings or adult unrelated donors (URD). Patients undergoing syngeneic or alternative donor 
HCT (e.g. umbilical cord blood or haploidentical) and those receiving ex vivo graft 
manipulation (T-cell depleted or CD34 selected grafts) were not included in the analysis. 
Patients undergoing a planned tandem auto-alloHCT (n=98) were not eligible. Patients 
receiving the prior autoHCT for indications other than DLBCL (n=275) were not included. 
Similarly, patients undergoing a post-autoHCT, allograft for indications other than relapsed 
or refractory DLBCL (e.g. graft failure, indolent NHL, therapy-related haematological 
malignancies etc.) were excluded.
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The intensity of alloHCT conditioning regimens was categorized as myeloablative or 
reduced intensity conditioning/non-myeloablative conditioning (RIC/NMA) using consensus 
criteria.(Bacigalupo et al, 2009) Previously established criteria for categorizing the degree of 
HLA matching were used for URDs. (Weisdorf et al, 2008) Complete remission (CR) to last 
therapy line before HCT on CIBMTR forms is defined as complete resolution of all known 
areas of disease on radiographic [computerized axial tomography (CAT) scan) assessments, 
while partial remission (PR) is defined as ≥50% reduction in the greatest diameter of all sites 
of known disease and no new sites of disease. Resistant disease is defined as <50% 
reduction in the diameter of all disease sites, or development of new disease sites.
 Study Endpoints
Primary outcomes were non-relapse mortality (NRM), progression/relapse, PFS and overall 
survival (OS). NRM was defined as death without evidence of lymphoma progression/
relapse; relapse was considered a competing risk. Progression/relapse was defined as 
progressive lymphoma after HCT or lymphoma recurrence after a CR; NRM was considered 
a competing risk. For PFS, a patient was considered a treatment failure at the time of 
progression/relapse or death from any cause. Patients alive without evidence of disease 
relapse or progression were censored at last follow-up. The OS was defined as the interval 
from the date of transplantation to the date of death or last follow-up. Acute (Przepiorka et 
al, 1995) and chronic (Shulman et al, 1980) graft-versus-host disease (GVHD) was defined 
and graded using established criteria. Neutrophil recovery was defined as the first of 3 
successive days with absolute neutrophil count (ANC) ≥ 0.5 × 109/l after post-
transplantation nadir. Platelet recovery was considered to have occurred on the first of three 
consecutive days with platelet count 20 × 109/l or higher, in the absence of platelet 
transfusion for 7 consecutive days. For neutrophil and platelet recovery, death without the 
event was considered a competing risk.
 Statistical analysis
Probabilities of PFS and OS were calculated as described previously.(Zhang et al, 2007) 
Cumulative incidence of NRM, lymphoma progression/relapse and haematopoietic recovery 
were calculated to accommodate for competing risks.(Zhang & Zhang, 2011) Associations 
among patient-, disease- and transplantation-related variables and outcomes of interest were 
evaluated using Cox proportional hazards regression. Backward elimination was used to 
identify covariates that influenced outcomes. Covariates with a p<0.05 were considered 
significant. The proportional hazards assumption for Cox regression was tested by adding a 
time-dependent covariate for each risk factor and each outcome. Covariates violating the 
proportional hazards assumption were added as time-dependent covariates in the Cox 
regression model. Interactions between the main effect and significant covariates were 
examined. Results are expressed as hazard ratio (HR). The variables considered in 
multivariate analysis are shown in Supplemental Table 1. To evaluate the impact of GVHD 
on transplantation outcomes, multivariate analyses were performed using Cox proportional 
hazards models, where the main-effect variable was defined as the time-dependent 
occurrence of acute grade II-IV GVHD or chronic GVHD versus neither. Each step of model 
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building included the main-effect. Factors with a p<0.05 were kept in the final model. The 
potential interactions between the main effect and all significant risk factors were tested. All 
statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
 Prognostic model for PFS
To develop a prognostic model able to predict PFS of DLBCL patients undergoing an 
alloHCT after a failed prior autoHCT, a Cox regression method was used to identify 
potential patient- and disease-related risk factors associated with treatment failure (failure 
event of PFS), using backward elimination with p<0.05 to enter and remove factors from the 
model. The results were then confirmed using a stepwise selection procedure and a forward 
selection. The risk factors considered in the model-building procedure are shown in 
Supplemental Table 1. Risk scores between 0 and 5 were assigned based on the ratios of log 
HRs. The risk scores were then plotted using the Kaplan-Meier (KM) curves and fitted in the 
Cox proportional hazards model to classify risk scores into different risk groups based on 
their distribution of the KM curves and HRs of the Cox model. PFS probabilities of the 
developed risk groups were calculated using the KM estimates.
 RESULTS
 Patient Characteristics
Between 2000 and 2012, 503 DLBCL patients undergoing an alloHCT after experiencing 
disease relapse or progression following a prior autoHCT were reported to the CIBMTR. 
Patient characteristics are described in Table I. Briefly, median age at alloHCT was 52 years, 
with the majority of patients being Caucasian/white (88%). Fifty-four per cent had advanced 
stage disease at diagnosis and at the time of alloHCT, 10% had bulky disease and 32% had 
extranodal involvement. The median number of prior therapies before alloHCT was 4. Prior 
to alloHCT, 74% had chemosensitive disease. RIC/NMA conditioning regimens were used 
in 376 subjects (75%) and peripheral blood was the most common graft source (91%). 
Donors were balanced between related (50%) and unrelated (50%). Median time interval 
between autoHCT and alloHCT (TIBAA) was 15 months.
 Univariate Outcomes
The probabilities of neutrophil recovery at day 28 and at day 100 were 94% (95% 
confidence interval; [CI]: 92–96) and 96% (95%CI: 94–98), respectively. The probabilities 
of platelet recovery at day 28 and day 100 were 83% (95%CI: 78–86) and 89% (95%CI: 86–
92), respectively (Table II). The cumulative incidence of grade II-IV acute GVHD at day 
+100 was 36% (95%CI = 28–44) and chronic GVHD at 1 year was 40% (95%CI = 35–44).
Median follow-up of survivors was 55 months (range 1–149). The probabilities of NRM at 
1, 3 and 5 years were 23% (95%CI: 19–27), 30% (95%CI: 26–34) and 31% (95%CI: 27–
36), respectively (Figure 1A). The probabilities of disease progression/relapse at 1, 3 and 5 
years were 33% (95%CI: 29–37), 38% (95%CI: 34–43) and 40 % (95%CI: 36–45) (Figure 
1B). The probabilities of PFS at 1, 3 and 5 years were 44% (95%CI: 40–48), 31% (95%CI: 
27–36) and 29% (95%CI: 24–33), respectively (Figure 1C), and those for OS were 54% 
(95%CI: 49–58), 37% (95%CI: 32–41) and 34% (95%CI: 30–39), respectively (Figure 1D).
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On multivariate analysis, chemoresistant disease before HCT (HR=1.86, 95%CI:1.23–2.81; 
p=0.003) and URD transplantation (HR=1.44, 95%CI:1.04–2.00; p=0.03) were associated 
with a higher risk of NRM (Table III). Use of myeloablative conditioning displayed a time-
varying effect on the risk of NRM. During the first 10 months post-transplant it was 
associated with a higher NRM (HR=1.99, 95%CI:1.34–2.95; p=0.001), but not beyond 10 
months post-alloHCT (HR=0.59; p=0.23). Multivariate analysis for disease progression/
relapse demonstrated that KPS <80 (HR=1.81, 95%CI:1.18–2.77; p=0.006) and 
chemoresistant disease (HR=2.25, 95%CI:1.51–3.36; p<0.0001) were associated with a 
higher risk of progression/relapse post-alloHCT (Table III). TIBAA displayed a time-
varying effect on the risk of disease progression/relapse. During the first year post-alloHCT, 
a short (<12 months) TIBAA was associated with a higher progression/relapse risk 
(HR=2.28, 95%CI:1.66–3.14; p<0.0001), but not beyond first year post-alloHCT (HR=0.51; 
p=0.14).
Patients with KPS <80 (HR-1.79, 95%CI:1.29–2.48; p=0.0005), chemoresistant disease 
(HR=2.04, 95%CI:1.53–2.73; p<0.0001), short TIBAA (<12 months) (HR-1.32, 95%CI:
1.06–1.64: p=0.01) and use of use of myeloablative conditioning (HR-1.29, 95%CI:1.09–
1.63; p=0.03) had a higher risk of therapy failure (i.e. inferior PFS) (Table III).
On multivariate analysis a higher risk of mortality (i.e. inferior OS) was associated with with 
KPS <80 (HR-1.86, 95%CI:1.33–2.60; p=0.0003), chemoresistant disease (HR=1.94, 
95%CI:1.44–2.61; p<0.0001) and myeloablative conditioning (HR=1.39, 95%CI:1.09–1.78; 
p=0.008). Graft type displayed a time-varying effect on the risk of mortality. During the first 
3 months post-transplant, peripheral blood grafts were associated with a lower risk of 
mortality (HR=0.37, 95%CI:0.22–0.61; p<0.0001), but not beyond 3 months post-alloHCT 
(HR=1.43; p=0.25). (Table III).
Development of acute GVHD (HR=2.24, 95%CI:1.24–4.04; p=0.007) and chronic GVHD 
(HR=1.72, 95%CI:1.06–2.82; p=0.03) was associated with higher risk of NRM. Neither 
acute, nor chronic GVHD were associated with risk of disease relapse/progression (data not 
shown). Acute GVHD was associated with a higher risk of mortality (HR=1.85, 95%CI:
1.27–2.69; p=0.001). Chronic GVHD was not associated with mortality risk (p=0.54).
 CIBMTR Prognostic Model for PFS
Three significant prognostic factors were included in the final model predicting post-
alloHCT PFS: KPS, chemosensitivity status and TIBAA. The final model only included 
those patients who had no missing data regarding KPS, chemosensitivity and TIBAA 
(n=417). Based on the ratios of log HRs in the final model, chemoresistant disease was 
assigned 5 points, KPS of <80 4 points and TIBAA <12 months was assigned 2 points 
(Table IV). Therefore, the total risk score for any individual patient using the 3 significant 
prognostic factors ranged from 0 to 11. Table IV summarizes the performance of the 
prognostic model. Distribution of patients by total risk score was as follows: 194 patients 
had a total risk score of 0 (reference category), 103 patients had a total risk score of 2 
(HR=1.30 range, 0.97 to 1.76), 14 patients had a total risk score of 4 (HR=1.41 range, 0.76 
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to 2.62), 38 patients had a total risk score of 5 (HR=1.66 range, 1.13 to 2.46), 12 patients 
had a total risk score of 6 (HR=2.21 range, 1.19 to 4.11), 35 patients had a total risk score of 
7 (HR=2.34 range, 1.58 to 3.47), 3 patients had a total risk score of 9 (HR=1.79 range, 0.44 
to 7.24) and 18 patients had a total risk score of 11 (HR=5.47 range, 3.26 to 9.19).
Based on the HRs and the distribution of the KM curves across the total risk score categories 
(Supplemental Figure 1S), we classified each patient into four prognostic risk groups: low-
risk group (score = 0), intermediate-risk group (score = 2 to 5), high-risk group (score = 6 to 
9) or very high-risk group (score = 11). Statistical significance was reached when we 
compared the PFS between low and intermediate group (p=0.01), low and high-risk group 
(p<0.0001) and low and very high-risk group (p<0.0001) (Table IV). The 1-year PFS 
probabilities for the low, intermediate, high and very high-risk groups were 54% (95% 
CI=47–61), 40% (95% CI=33–48), 26% (95% CI=14–38) and 6% (95% CI=0–16), 
respectively. The probability for 3-year PFS was 40% (95% CI:32–47), 32% (95% CI=25–
40), 11% (95% CI:2–20) and 6% (95% CI:0–16) respectively, for the three prognostic 
groups (Figure 2A). The prognostic model also predicted OS following alloHCT (Table IV). 
The 1-year OS probabilities for the low, intermediate, high and very high-risk groups were 
63% (95% CI=57–70), 52% (95% CI=44–60), 38% (95% CI=25–51) and 17% (95% CI=0–
34), respectively. The probability for 3-year OS was 43% (95% CI:36–51), 39% (95% 
CI=31–46), 19% (95% CI:8–31) and 11% (95% CI:0–26) respectively, for the three 
prognostic groups (Figure 2A).
 Impact of conditioning intensity
Compared to RIC/NMA conditioning, the patients receiving myeloablative alloHCT were 
younger (median age 53 years vs. 48 years; p=0.0001), more likely to have chemoresistant 
disease (19% [n=71] vs. 28% [n=35]; p=0.04) and similar KPS (p=0.54). Table V 
summarizes survival outcomes of the study population stratified according conditioning 
intensity. In patients receiving myeloablative conditioning compared to RIC/NMA, the 5-
year adjusted probabilities of PFS (27% vs. 30%; p=0.47, Figure 3A) and OS (28% vs. 37%; 
p=0.055, Figure 3B) were not significantly different. Restricting analysis to chemoresistant 
patients, the 5-year adjusted probabilities of PFS (13% vs. 18%; p=0.47, Figure 3C) and OS 
(15% vs. 25%; p=0.22, Figure 3D) in similar order, were not significantly different.
 Causes of Death
At a median follow-up of 55 months, 325 patients were no longer alive. The most common 
cause of death post-alloHCT was relapsed DLBCL (N=142, 44% of all deaths). GVHD 
accounted for 9% (n=28) of deaths, while infections were responsible for 19% of mortality 
(n=61). For details please see Table 2S.
 DISCUSSION
Prognostic models predicting outcomes of alloHCT in DLBCL failing a prior autoHCT are 
currently not available. Here, we have performed a registry analysis of DLBCL patients 
undergoing alloHCT after a failed prior autograft. This analysis provides several important 
observations: (i) NRM (23% at 1-year, 30% at 3-years) remains significant following 
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alloHCT, (ii) a prognostic model based on factors readily available prior to alloHCT 
(TIBAA, chemosensitivity status, KPS) was developed for pre-transplant patient 
counselling, (iii) GVHD increased risk of non-relapse and overall mortality without reducing 
risk of relapse/progression and (iv) myeloablative conditioning provides no benefit in this 
setting, including in the subset of patients with chemoresistant disease.
There is evidence to support a possible GVL effect in DLBCL, including long-term 
responses in chemoresistant patients undergoing RIC alloHCT,(Hamadani et al, 2013) and 
responses to donor lymphocyte infusion and/or withdrawal of immune suppression.(Bishop 
et al, 2008, Thomson et al, 2009) Because of the potential for a GVL effect in DLBCL, 
combined with the poor prognosis associated with relapse after autoHCT, such patients are 
often considered for alloHCT. Notably, in the current analysis no benefit of acute or chronic 
GVHD was seen, in terms of reducing the risk of disease progression/relapse. These 
observations are in line with another recent large CIBMTR analysis.(Urbano-Ispizua et al, 
2015)
The decision to proceed with alloHCT in DLBCL after a failed autograft is complex because 
many of these patients have advanced age, impaired performance status or comorbid 
conditions that may limit their candidacy for alloHCT. For example, in one study, only 19% 
of patients who relapsed or progressed after autoHCT ultimately underwent an alloHCT.
(Rigacci et al, 2012) Among DLBCL patients undergoing alloHCT after a failed autograft, 
no tools are available to estimate HCT survival outcomes for patient counselling. The 
CIBMTR prognostic score reported in this study is not only easy to use, but utilizes 
information readily available prior to alloHCT (response to last therapy before alloHCT, 
KPS at HCT and TIBAA). This prognostic model is not designed to be applied to DLBCL 
patients at the time of their initial relapse after autoHCT (e.g. to determine their candidacy 
for salvage therapies or for a future alloHCT), but rather as a tool to be used immediately 
prior to alloHCT for estimating transplantation outcomes for patient counselling.
To date, there have only been three previous studies that have focused specifically on 
alloHCT outcomes in DLBCL patients who progressed after a prior autoHCT (Table VI).
(Rigacci et al, 2012, van Kampen et al, 2011, Kim et al, 2014) These studies (which largely 
focused on patients who underwent alloHCT from 1995–2008) showed approximately 30–
40% PFS; however each study was limited by relatively short follow-up (median 2–3 years), 
and limited patient numbers (30–165 patients). Potentially partly due to these limitations, 
these three studies had conflicting results regarding factors predicting improved PFS and OS 
after alloHCT. In contrast, the current study is strengthened by a large number of patients 
(n=503), treated in a more contemporary era (2000–2012), with a median follow up of 4.6 
years.
Our study found a NRM rate of 23% at 1 year and 30% at 3 years. This is in line with other 
studies looking at alloHCT following a failed autoHCT in DLBCL patients, in which the 
rate of NRM was 17–28% at 3–5 years. (Rigacci et al, 2012, van Kampen et al, 2011, Kim et 
al, 2014) In the current study KPS <80, chemoresistant disease, a TIBAA < 1-year and 
myeloablative conditioning were all predictive of worse survival outcomes on multivariate 
analysis, generally in line with predictive factors reported in prior studies (Table IV). It is 
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worth noting that in the European Group of Blood and Marrow Transplantation (EBMT) 
study,(van Kampen et al, 2011) a time from autoHCT to post-autograft relapse of < 1-year 
was predictive of PFS. In contrast we used TIBAA in this study, since the interval between 
autoHCT and post-autograft relapse is not captured for all patients in the CIBMTR registry. 
The TIBAA is not only easily imputable immediately prior to alloHCT, but (for the patients 
in the CIBMTR registry for whom interval between autoHCT and post-autoHCT relapse was 
captured) it also correlates closely with the interval between autoHCT and post-autoHCT 
relapse (data not shown).
We found no benefit of myeloablative conditioning in this study, even in the subset of 
chemoresistant patients. In fact, myeloablative conditioning was associated with increased 
NRM, inferior PFS as well as OS on multivariate analysis. These observations are consistent 
with prior CIBMTR data showing no benefit of myeloablative conditioning in 
chemoresistant DLBCL.(Hamadani et al, 2013) Our results indicate that the same holds true 
in the setting of DLBCL patients who have undergone a prior autoHCT.
Our study has limitations. The nature of data captured in the CIBMTR registry precludes 
comparison against DLBCL patients failing an autoHCT but never undergoing a subsequent 
alloHCT. In a recent CIBMTR study,(Hamadani et al, 2014) among DLBCL patients 
undergoing autoHCT who experienced disease relapse, the 3-year post-relapse OS was 19% 
(unpublished data). These unpublished observations should however, be used with caution to 
ascertain the relative benefit of alloHCT in this setting. Other limitations of the current 
analysis include the lack of information regarding pre-alloHCT PET status, as well as 
biomarkers known to affect prognosis in DLBCL, such as cytogenetic abnormalities (MYC, 
BCL2, and BCL6 rearrangements) or “cell-of-origin” profile (germinal centre versus 
activated B-cell). However it was recently reported that pre-alloHCT PET status in NHL 
does not predict PFS or OS.(Bachanova et al, 2015) In addition, while the presence of MYC 
rearrangement is associated with inferior PFS and OS following HCT (Thieblemont et al, 
2011), the available literature would indicate that “cell-of-origin” profile fails to predict 
outcomes following HCT.(Moskowitz et al, 2005, Gu et al, 2012)
In conclusion, we were able to construct a CIBMTR prognostic model to predict PFS after 
alloHCT, using KPS, TIBAA and chemoresistance at alloHCT. This tool was able to 
discriminate 3-year PFS, ranging from 38% down to 10%. This same prognostic tool was 
able to discriminate 3-year OS, ranging from 43% down to 14%. This prognostic index 
should help provide a more accurate estimate of risks and benefits with alloHCT, when 
counselling DLBCL patients before a planned alloHCT. This prognostic model requires 
independent validation, possibly by analysing data reported to other transplantation 
registries (e.g. EBMT registry). The CIBMTR prognostic model is not designed to assess 
suitability of DLBCL patient for a future allograft, at the time of their initial post-autograft 
relapse. On the other hand, these data also illustrate the shortcomings of alloHCT for this 
patient population. Further gains will need to be achieved in reducing NRM as well as 
augmenting GVL effects in order for alloHCT to achieve more widespread applicability for 
DLBCL patients relapsing after autoHCT. Rationally designed clinical trials that integrate 
novel agents (such as immune checkpoint inhibitors, antibody-drug conjugates and B-cell 
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receptor signalling inhibitors) and/or novel cellular therapies (such as chimeric antigen 
receptor technology) with alloHCT may help to achieve this goal.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Outcomes for DLBCL patients undergoing allogeneic HCT after a prior failed 
autologous HCT
Cumulative incidence of (1A) non-relapse mortality, (1B) disease progression/relapse, (1C) 
progression-free survival and (1D) overall survival.
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Figure 2. Prognostic index for DLBCL patients undergoing allogeneic HCT (alloHCT) after a 
prior failed autologous HCT (autoHCT)
Three adverse prognostic factors were used to construct a prognostic model for PFS, 
including KPS <80 (4 points), interval between autoHCT and alloHCT of <1 year (2 points) 
and chemoresistant disease at alloHCT (5 points). This classified patients into four groups: 
low-risk (0 points), intermediate-risk (2–5 points), high-risk (6–9 points) or very high-risk 
(11 points). (2A) Progression-free survival and (2B) overall survival based on CIBMTR 
prognostic index.
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Figure 3. Overall survival (OS) and progression-free survival (PFS) of DLBCL patients 
undergoing allogeneic HCT after a prior failed autologous HCT, stratified by conditioning 
intensity
PFS of all patients (3A), OS of all patients (3B), PFS of chemoresistant patients (3C) and 
OS of chemoresistant patients (3D).
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Table I
Characteristics of patients who underwent an allogeneic transplant after a failed autologous transplant for 
DLBCL from 2000–2012 reported to the CIBMTR. (Italicized text indicates variables available in CRF-level 
data patients).
Number of patients 503
Number of CRF-level data patients 155
Number of centres 133
Median age at transplant, years (range) 52 (19–72)
Male gender 305 (61)
Race
    Caucasian/White 444 (88)
    Black 17 (3)
    Others1 33 (7)
    Missing 9 (2)
Karnofsky Performance Score
    80–100% 393 (78)
    <80% 52 (10)
    Missing 58 (12)
Stage III/IV at Diagnosis 83 (54)
Remission status at HCT
    Complete remission 175 (35)
    Partial remission 197 (39)
    Chemorefractory 106 (21)
    Untreated 12 (2)
    Unknown 13 (3)
Rituximab prior to HCT 112 (72)
Radiation therapy prior to HCT 98 (63)
Lines of therapy prior to alloHCT
    Median (range) 4 (1–7)
History of transformation from indolent histology 25 (16)
Elevated lactate dehydrogenase at HCT 52 (34)
Active extranodal disease at HCT 49 (32)
Bone marrow involvement at HCT
    No bone marrow involvement 141 (91)
    Bone marrow involvement 7 (5)
    Missing 7 (5)
Bulky Disease (>5 cm) at HCT 15 (10)
Conditioning regimen intensity
    Myeloablative 127 (25)
    Reduced intensity conditioning 376 (75)
TBI in conditioning regimens
    Myeloablative doses of TBI 41 (8)
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Graft type
    Bone marrow 47 (9)
    Peripheral Blood 456 (91)
Type of donor
    HLA-identical sibling 253 (50)
    Unrelated well-matched 118 (23)
    Unrelated partially matched 132 (26)
Donor-Recipient CMV Status
    −/+ 102 (20)
    Other 226 (45)
    Missing 175 (35)
GVHD Prophylaxis
    CNI + MMF +- others 180 (36)
    CNI + MTX +-others (except MMF) 219 (43)
    CNI + others (except MTX, MMF) 64 (13)
    Other GVHD prophylaxis2 7 (1)
    Missing GVHD prophylaxis 33 (7)
Antithymocyte globulin in conditioning 110 (22)
Alemtuzumab in conditioning 7 (1)
Year of Transplant
    2000–2003 111 (22)
    2004–2007 154 (31)
    2008–2012 238 (47)
Time from autoHCT to alloHCT
    Median (range) 15 (1–198)
    ≤12 months 201 (40)
    >12 months 302 (60)
Median follow-up of survivors (range), months 55 (1–149)
HCT=haematopoietic cell transplantation; alloHCT=allogeneic haematopoietic cell transplantation; autoHCT= autologous haematopoietic cell 
transplantation; TBI=total body irrdation; CMV=Cytomegalovirus; GVHD=graft-versus-host disease; CNI=calcineurin inhibitor; 
MMF=mycophenolate mofetil; MTX=methotrexate
1
Asian (n=25), Native American (n=1), Pacific Islander (n=1), other (n=6)
2
MMF/Campath (n=1), MMF/Sirolimus (n=1), MTX(n=3), MMF/MTX(n=1), MMF/MTX/Sirolimus (n=1)
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Table II
Haematopoietic recovery, graft-versus-host disease and survival outcomes
Outcomes Evaluated (n) Probability (95% CI)
Neutrophil recovery >0.5 × 109/l 478
    28-day 94 (92–96)%
    100-day 96 (94–98)%
Platelet recovery ≥ 20 × 109/l 374
    28-day 83 (78–86)%
    100-day 89 (86–92)%
Acute GVHD (II-IV)* 151
    100-day 36 (28–44)%
Acute GVHD (III-IV)* 151
    100-day 15 (10–21)%
Chronic GVHD 454
    6 month 26 (22–30)%
    1-year 40 (35–44)%
    3-year 47 (42–51)%
Extensive chronic GVHD 454
    1-year 33 (28–37)%
NRM 494
    1-year 23 (19–27)%
    3-year 30 (26–34)%
    5-year 31 (27–36)%
Relapse/Progression 494
    1-year 33 (29–37)%
    3-year 38 (34–43)%
    5-year 40 (36–45)%
Progression-free Survival 494
    1-year 44 (40–48)%
    3-year 31 (27–36)%
    5-year 29 (24–33)%
Overall survival 503
    1-year 54 (49–58)%
    3-year 37 (32–41)%
    5-year 34 (30–39)%
*
Applies to patients with CRF-level data
GVHD = graft-versus-host disease; NRM = non-relapse mortality; CI = confidence interval.
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Table V
Allogeneic transplantation outcomes stratified according to transplantation conditioning intensity.
Myeloablative conditioning
Adjusted probability (95% CI)
Reduced-intensity or non-
myeloablative conditioning
Adjusted probability (95% CI)
p-value
Progression-free survival N= 126 N=368
1-year 36 (26–44)% 46 (42–51)% 0.03
3-year 29 (21–36)% 33 (28–37)% 0.39
5-year 27 (19–34)% 30 (25–35)% 0.47
Overall survival N=127 N=376
1-year 44 (36–52)% 56 (52–61)% 0.01
3-year 31 (23–39)% 39 (34–44)% 0.12
5-year 28 (20–36)% 37 (32–42)% 0.055
Chemoresistant patients only
Progression-free survival N=35 N=69
1-year 16 (4–27)% 33 (23–44)% 0.03
3-year 13 (2–24)% 20 (11–29)% 0.31
5-year 13 (2–24)% 18 (9–27)% 0.47
Overall survival N=35 N=71
1-year 23 (10–37)% 45 (33–56)% 0.02
3-year 15 (3–27)% 29 (19–39)% 0.09
5-year 15 (3–27)% 25 (15–35)% 0.22
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